Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ferring Acquires Orthobiologic Assets from BioSET | Contract Pharma

What are you searching for?

Sign in
Breaking News

Ferring Acquires Orthobiologic Assets from BioSET

AMPLEX and PREFIX are ready for Phase III

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ferring Pharmaceuticals has acquired two Phase III orthobiologic product candidates from BioSurface Engineering Technologies, Inc. (BioSET). The drugs, AMPLEX and PREFIX, will be investigated in foot/ankle and lumbar spine fusion surgical procedures, respectively. Both drugs are based on a biomimetic peptide designed to enhance the body’s own natural mechanisms of bone repair.

“With the acquisition of the BioSET portfolio, Ferring intends to build on its growing success in orthopaedics,” said Michel Pettigrew, president of the Ferring executive board and chief operating officer, “By developing new orthobiologic products for joint fusion, we will expand and diversify our offering to include innovative solutions for orthopaedic surgery.”

In addition to AMPLEX and PREFIX, Ferring has acquired a library of rationally designed biomimetic peptides intended for applications in bone and tissue repair.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics